Stockreport

NeuroSense Therapeutics Announces $5 Million Private Placement at Premium to Market Price

NeuroSense Therapeutics Ltd.  (NRSN) 
PDF CAMBRIDGE, Mass., Dec. 2, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel t [Read more]